Bexotegrast Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Bexotegrast Growth

• Novel dual integrin inhibition mechanism directly targets fibrosis biology

Bexotegrast selectively inhibits αvβ6 and αvβ1 integrins, which are major activators of transforming growth factor-beta (TGF-β), a central driver of fibrosis. Unlike currently approved IPF therapies that mainly slow disease progression, bexotegrast is designed to directly suppress fibrotic tissue remodeling and collagen deposition. This differentiated mechanism has generated strong scientific interest because TGF-β signaling is implicated across multiple fibrotic diseases including IPF, PSC, and liver fibrosis.

• Encouraging Phase II IPF data supports disease-modifying potential

In the Phase IIa INTEGRIS-IPF trial, bexotegrast demonstrated favorable safety and tolerability across multiple dose groups, with exploratory efficacy signals including stabilization of forced vital capacity (FVC), reductions in quantitative lung fibrosis, and improvement in fibrosis biomarkers. Importantly, the drug was tested both as monotherapy and on top of standard therapies such as nintedanib and pirfenidone, supporting potential combination use in clinical practice.

• Imaging and collagen biomarker studies strengthen mechanistic validation

A 2025 Phase II PET imaging study published on PubMed demonstrated that bexotegrast reduced active type I collagen deposition in IPF patients after 12 weeks of treatment. The study used advanced ^68Ga-CBP8 PET imaging to directly visualize collagen activity in lung tissue, providing rare mechanistic evidence that the therapy may reduce ongoing fibrosis formation. Such biomarker validation is highly valuable in fibrosis drug development and improves confidence in long-term clinical efficacy.

• Large unmet need in IPF creates substantial commercial opportunity

IPF is a progressive and fatal fibrotic lung disease with median survival of approximately 3-5 years after diagnosis. Existing therapies such as nintedanib and pirfenidone slow lung-function decline but are associated with tolerability limitations and do not reverse fibrosis. Because bexotegrast may offer a more targeted anti-fibrotic approach with potential combination utility, it could capture meaningful market share if efficacy is confirmed in later-stage studies. Current approved IPF therapies already generate multi-billion-dollar annual sales globally, demonstrating the strong commercial potential of successful fibrosis drugs.

• Expansion potential into PSC and other fibrotic diseases broadens revenue outlook

Beyond IPF, bexotegrast is also being developed for PSC, another severe fibrotic disease with no approved pharmacologic therapies. Earlier PSC data showed reductions in liver stiffness, alkaline phosphatase (ALP), and fibrosis markers, generating optimism within the PSC patient and hepatology communities. The drug’s mechanism may also support future expansion into broader fibrotic indications, significantly increasing its long-term market potential.

Bexotegrast Recent Developments

In June 2025, Pliant announced it would discontinue the development of bexotegrast for IPF after a data review of the BEACON-IPF trial showed an "unfavourable risk-benefit profile”. While the IPF program stopped, the company continues to develop bexotegrast for Primary Sclerosing Cholangitis (PSC), with Phase II trial data indicating a favorable safety profile and positive trends in liver fibrosis biomarkers.  
“Bexotegrast Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of Bexotegrast for potential indication like Graves ophthalmopathy in the 7MM. A detailed picture of Bexotegrast’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Bexotegrast for potential indications. The Bexotegrast market report provides insights about Bexotegrast’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Bexotegrast performance, future market assessments inclusive of the Bexotegrast market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Bexotegrast sales forecasts, along with factors driving its market.

Bexotegrast Drug Summary

Bexotegrast (formerly PLN-74809) is an orally administered, small-molecule dual-selective integrin inhibitor developed by Pliant Therapeutics for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The drug selectively inhibits the αvβ6 and αvβ1 integrins, key activators of transforming growth factor-β (TGF-β), a central signaling pathway involved in tissue fibrosis and chronic inflammation. By blocking TGF-β activation locally at sites of injury, bexotegrast aims to reduce fibroblast activation, extracellular matrix deposition, and progressive organ scarring while minimizing systemic toxicities associated with broad TGF-β inhibition. Clinical studies have demonstrated favorable pharmacokinetics, tolerability, and anti-fibrotic activity, including reductions in fibrosis biomarkers and stabilization of disease parameters in patients with IPF and PSC. The drug has received FDA Fast Track designation for IPF, and ongoing Phase II clinical trials continue to evaluate its potential as a disease-modifying therapy for chronic fibrotic disorders with significant unmet medical need. The report provides Bexotegrast’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Bexotegrast Market Report

The report provides insights into:

• A comprehensive product overview including the Bexotegrast MoA, description, dosage and administration, research and development activities in potential indication like Graves ophthalmopathy.
• Elaborated details on Bexotegrast regulatory milestones and other development activities have been provided in Bexotegrast market report.
• The report also highlights Bexotegrast‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Bexotegrast market report also covers the patents information, generic entry and impact on cost cut.
• The Bexotegrast market report contains current and forecasted Bexotegrast sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Bexotegrast market report also features the SWOT analysis with analyst views for Bexotegrast in potential indications.

Methodology

The Bexotegrast market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Bexotegrast Analytical Perspective

• In-depth Bexotegrast Market Assessment

This Bexotegrast sales market forecast report provides a detailed market assessment of Bexotegrast for potential indication like Graves ophthalmopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Bexotegrast sales data uptil 2034.

• Bexotegrast Clinical Assessment

The Bexotegrast market report provides the clinical trials information of Bexotegrast for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Bexotegrast Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Bexotegrast Market Potential & Revenue Forecast

• Projected market size for the Bexotegrast and its key indications
• Estimated Bexotegrast sales potential (Bexotegrast peak sales forecasts)
• Bexotegrast Pricing strategies and reimbursement landscape

Bexotegrast Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Bexotegrast Market positioning compared to existing treatments
• Bexotegrast Strengths & weaknesses relative to competitors

Bexotegrast Regulatory & Commercial Milestones

• Bexotegrast Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Bexotegrast Clinical Differentiation

• Bexotegrast Efficacy & safety advantages over existing drugs
• Bexotegrast Unique selling points

Bexotegrast Market Report Highlights

• In the coming years, the Bexotegrast market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Bexotegrast companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Bexotegrast’s dominance.
• Other emerging products for Graves ophthalmopathy are expected to give tough market competition to Bexotegrast and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Bexotegrast in potential indications.
• Analyse Bexotegrast cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Bexotegrast sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Bexotegrast in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Bexotegrast? How strong is Bexotegrast’s clinical and commercial performance?
• What is Bexotegrast’s clinical trial status in each individual indications such as Graves ophthalmopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Bexotegrast Manufacturers?
• What are the key designations that have been granted to Bexotegrast for potential indications? How are they going to impact Bexotegrast’s penetration in various geographies?
• What is the current and forecasted Bexotegrast market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Bexotegrast in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Bexotegrast for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Bexotegrast? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.